Positrigo gets CE mark for brain PET system

AuntMinnie.com staff writers
Oct 8, 2024

Nuclear medicine technology firm Positrigo of Zurich, Switzerland, has secured European market clearance for its dedicated brain PET system, NeuroLF.

NeuroLFNeuroLFImage courtesy of Positrigo

The imaging device is designed to help diagnose and monitor brain diseases such as Alzheimer's disease, brain tumors, epilepsy, Parkinson's disease, and others. The company received U.S. Food and Drug Administration clearance for NeuroLF in July.

Latest in Molecular Imaging
Pluvicto Spect Ct Response Thumbnail
SPECT/CT predicts treatment response in Pluvicto patients
November 1, 2024
New! Imaging Life Issue 20 now available
Sponsored
New! Imaging Life Issue 20 now available
November 5, 2024
Heart Attack
Ask cardiac PET patients how much they exercise, study suggests
October 30, 2024
2024 10 28 Meningioma Thumbnail
Intraarterial PRRT safe in patients with meningioma
October 28, 2024
Related Stories
Brain
Nuclear Medicine
Positrigo secures FDA clearance for brain PET system
F-18 SynVesT-1 images at early (0-10) and late (90-120 minute) times postinjection. There is clear identification of high flow regions in the early images. The late images show the synaptic (SV2A) pattern which differs from the flow pattern, e.g., in the thalamus. B. 11C-PHNO binding potential (BPND) images shown in transverse, coronal, and sagittal orientations of PET alone and PET overlaid with MRI. Left: Region of substantia nigra (green arrow, max display: 4.0). Right: Thalamic region (max: 2.5) showing focal bilateral binding in a specific thalamic nucleus (blue arrow, likely anteroventral nucleus). C. Sagittal images of 11C-LSN3172176 M1 muscarinic cholinergic BPND (max display: 10). D. R1 images of the same tracer (max: 2). Cerebellum (blue arrow) shows no specific binding (C) and high tracer delivery (D). E. 18F-FE-PE2I dopamine transporter BPND images (zoomed, max display: 6) showing striatum and substantia nigra (green arrow). F. R1 images of the same tracer (max: 2) with inset showing zoomed region in E.
2024
SNMMI: Image of the Year shows early brain nuclei activity
2024 10 07 Fes Pet Thumbnail
Molecular Imaging
FES-PET improves management of breast cancer patients
New! Imaging Life Issue 20 now available
Sponsor Content
New! Imaging Life Issue 20 now available
More in Molecular Imaging
SPECT/CT predicts treatment response in Pluvicto patients
By Will Morton
SPECT/CT scans taken just four hours after patients begin Lu-177 PSMA-617 treatment can help assess treatment responses.
November 1, 2024
Pluvicto Spect Ct Response Thumbnail
FCH-PET emerging in patients with hyperparathyroidism
By Will Morton
F-18 fluorocholine (FCH) PET/CT appears to be an effective first-line imaging method in patients with primary hyperparathyroidism.
October 31, 2024
Hyperparathyroidism
Ask cardiac PET patients how much they exercise, study suggests
By Will Morton
Exercise activity is an independent predictor of events such as heart attacks in patients undergoing stress PET myocardial perfusion imaging.
October 30, 2024
Heart Attack
Intraarterial PRRT safe in patients with meningioma
By Will Morton
Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.
October 28, 2024
2024 10 28 Meningioma Thumbnail
PSMA-PET provides long-term benefits
By Will Morton
Prostate-specific membrane antigen (PSMA) PET imaging could improve the length and quality of life for patients with recurrent prostate cancer.
October 24, 2024
Prostate Imaging2
New PET tracer improves detection of insulinomas
By Will Morton
A new PET/CT radiotracer that detects insulinomas could eliminate the need for other diagnostic procedures in a vast majority of patients.
October 21, 2024
Glp 1 R Pet 67169a712e569 Thumbnail
Tc-99m shortage expected into November
By Will Morton
The delayed restart of a nuclear research reactor in the Netherlands is expected to cause supply shortages of technetium-99m (Tc-99m) into November.
October 18, 2024
Isotopes
FAPI-PET shows value in staging lung cancer patients
By Will Morton
Fibroblast activation protein inhibitor (FAPI) PET/CT shows excellent diagnostic accuracy for detecting lymph node metastases in lung cancer patients
October 17, 2024
Lung Cancer
New guidelines cover theranostics for brain tumors
By Will Morton
The use of somatostatin receptor PET imaging and therapy in meningiomas is on the rise.
October 14, 2024
Brain
NNSA's Mo-99 program: A bumpy ride
By Will Morton
Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).
October 10, 2024
Mo 99
FES-PET improves management of breast cancer patients
By Will Morton
PET/CT imaging with F-18 fluroestradiol (FES) can play a significant role in helping clinicians make treatment decisions in patients with recurrent or metastatic breast cancer
October 7, 2024
2024 10 07 Fes Pet Thumbnail
What impact will flurpiridaz F-18 have on heart care?
By Will Morton
Seventeen years was all it took for flurpiridaz F-18 to reach the market, with the first patient injected with the PET imaging agent in November, 2007.
October 4, 2024
Maddahi
Page 1 of 598
Next Page